|

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

RECRUITINGPhase 1/2Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Actively Recruiting
PhasePhase 1/2
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Started2024-05-10
Est. completion2026-03
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06239298

Summary

This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-70 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
* Life expectancy ≥ 3 months.

Exclusion Criteria:

* Patients were deemed unsuitable for participating in the study by the investigator for any reasons.

Conditions2

CancerSolid Tumor

Interventions2

Donafenib Tosilate TabletsZG005 Powder for Injection

Related trials

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.